Thomas Christély has been named chief executive officer of Silence Therapeutics plc, an RNA interference (RNAi) therapeutics company. He will be based at Silence’s facility in Berlin. Mr. Christély has more than 20 years experience in corporate and business development and finance. He was involved in the merger that formed Silence, and has concluded collaborations with AstraZeneca, Pfizer, and Dainippon Sumitomo, as well as M&A, divestments and strategic restructurings. He joined Atug...